Dr. Daniel Frigo

The University of Texas MD Anderson Cancer Center

Dr. Daniel Frigo received his B.S. in biochemistry from the University of Notre Dame and earned his Ph.D. in molecular and cellular biology from Tulane University. He was then awarded a postdoctoral fellowship and appointed to research scientist within the Department of Pharmacology & Cancer Biology at Duke University Medical Center in Durham, NC. He was appointed to a faculty position as an Assistant Professor at the University of Houston’s Center for Nuclear Receptors & Cell Signaling and the Department of Biology & Biochemistry in 2010. In 2017, he moved his laboratory to The University of Texas MD Anderson Cancer Center where he is currently a tenured Associate Professor in the Departments of Cancer Systems Imaging (primary) and Genitourinary Medical Oncology (secondary). He remains an Adjunct Associate Professor with the University of Houston. Dr. Frigo’s research is focused on understanding the basic biology of prostate cancer for the purpose of developing new therapies to treat the advanced stages of the disease. Currently, the Frigo laboratory is investigating how various signaling pathways, such as those regulated by the androgen receptor, CAMKK2, AMPK, mTOR, and MYC drive the progression of prostate cancer.